✦ LIBER ✦

Patient compliance with aggressive multimodal therapy in locally advanced breast cancer

✍ Scribed by David Berger; Albert Braverman; Chul K. Sohn; Monica Morrow

Publisher: John Wiley and Sons
Year: 1988
Tongue: English
Weight: 472 KB
Volume: 61
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19880401)61:7<1453::aid-cncr2820610729>3.0.co;2-#

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Medical adrenalectomy in patients with a

Medical adrenalectomy in patients with advanced breast cancer

✍ J. Shelton Horsley III; Heber H. Newsome; Peter W. Brown; James P. Neifeld; Jose 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 465 KB 👁 1 views

Radiotherapy in locally advanced cancer

Radiotherapy in locally advanced cancer of the breast. Adjunct to standard therapy

✍ Ruth Guttmann 📂 Article 📅 1967 🏛 John Wiley and Sons 🌐 English ⚖ 383 KB 👁 1 views

Radiation therapy in the management of l

Radiation therapy in the management of locally advanced and disseminated breast cancer

✍ Florence C. H. Chu 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 462 KB 👁 1 views

Tolerance of half-body irradiation as sy

Tolerance of half-body irradiation as systemic therapy for patients with locally advanced breast cancer

✍ Gocheva, Lilia; Todorov, Jordan; Danon, Samuel 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB 👁 1 views

Background.

Cyclophosphamide therapy in patients wit

Cyclophosphamide therapy in patients with advancing breast cancer following adrenalectomy and 5-fluorouracil

✍ Anthony J. Piro; Richard E. Wilson; Hans B. Nevinny 📂 Article 📅 1971 🏛 John Wiley and Sons 🌐 English ⚖ 334 KB 👁 1 views

Oral doxifluridine plus levoleucovorin i

Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer

✍ Emilio Bajetta; Laura Biganzoli; Carlo Carnaghi; Maria Di Bartolomeo; Ivo Spagno 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## BACKGROUND. There currently is no agreement regarding the appropriate treatment of elderly patients with advanced breast carcinoma (ABC). Doxifluridine (5-dFUR), a prodrug of 5-fluorouracil, has been found to be effective in this entity, but its use is limited by neurotoxicity and cardiotoxici